Clinical Trials for Disease-Modifying Drugs Such as BACE Inhibitors

BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease

Volumn , Issue , 2010, Pages 197-216

  Hsu, Henry H ^a  

^a CoMentis Inc ^*  (United States)

Author keywords

BACE, lead target for orchestrated therapy of Alzheimer's disease; Clinical trials for disease modifying drugs as BACE inhibitors; Potential disease modifying therapies for AD

Indexed keywords

EID: 84655170329     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470594087.ch9     Document Type: Chapter

References (70)

1. Maslow, K. 2008 . 2008 Alzheimer ' s disease facts and figures . Alzheimers Dement 4 ( 2 ): 110-133 .
2. Blennow, K., de Leon, M.J., Zetterberg, H. 2006 . Alzheimer ' s disease . Lancet 368 ( 9533 ): 387-403 .
3. Terry, A.V., Jr. and Buccafusco, J.J. 2003 . The cholinergic hypothesis of age and Alzheimer ' s disease-related cognitive deficits; Recent challenges and their implications for novel drug development . J Pharmacol Exp Ther 306 ( 3 ): 821-827 .
4. Birks, J. 2006 . Cholinesterase inhibitors for Alzheimer ' s disease . Cochrane Database Syst Rev ( 1 ):CD005593.
5. Salloway, S., Mintzer, J., Weiner, M.F., and Cummings, J.L. 2008 . Disease-modifying therapies in Alzheimer ' s disease . Alzheimers Dement 4 ( 2 ): 65-79 .
6. Cummings, J.L., Doody, R., and Clark, C. 2007 . Disease-modifying therapies for Alzheimer disease . Neurology 69 ( 16 ): 1622-1634 .
7. Schenk, D., Barbour, R., Dunn, W. et al. 1999 . Immunization with A β attenuates Alzheimer ' s disease-like pathology in the PDAPP mouse . Nature 400 : 173-177 .
8. Janus, C., Pearson, J., and McLaurin, J. 2000 . A β immunization reduces behavioural impairment and dense-cored plaques in a model of Alzheimer ' s disease . Nature 408 : 979-982 .
9. Morgan, D. 2005 . Mechanisms of A β plaque clearance following passive A β immunization . Neurodegen Dis 2 : 261-266 .
10. Levites, Y., Smithson, L.A., Price R.W., Dakin, R.S., Yuan, B., Sierks, M.R. et al. 2006 . Insights into the mechanisms of action of anti-A β antibodies in Alzheimer ' s disease mouse models . The FASEB Journal 20 : 2576-2578 .
11. Lichtlen, P. and Mohajeri, M.H. 2008 . Antibody-based approaches in Alzheimer ' s resarch; safety, pharmacokinetics, metabolism and analytical tools . J Neurochem 104 ( 4 ): 859-874 .
12. Gilman, S., Koller, M., Black, R., Jenkins, L., Griffith, S., Fox, N. et al. 2005 . Clinical effects of A β immunization (AN1792) in patients with AD in an interrupted trial . Neurology 64 : 1553-1562 .
13. Hock, C., Konietako, U., Streffer, J.R., Tracy, J., Signorell, A., Muller-Tillmanns, B. et al. 2003 . Antibodies against beta-amyloid slow cognitive decline in Alzheimer ' s disease . Neuron 38 : 547-554 .
14. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A. et al. 2008 . Long-term effects of A β 42 immunisation in Alzheimer ' s disease: follow-up of a randomised, placebo-controlled phase 1 trial . The Lancet 372 : 216-223 .
15. Grundman, M. and Black, R. 2008 . Clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer ' s disease . Alzheimers Dement 4 ( 4, Suppl 2 ):T166.
16. Wolfe, M.S. and Haass, C. 2001 . The role of presenilins in gamma-secretase activity . J Biol Chem 276 : 5413-5416 .
17. Kimberly, W.T. and Wolfe, M.S. 2003 . Identity and function of y-secretase . J Neurosci Res 74 : 353-360 .
18. Hartmann, D., Tournoy, J., and Saftig, P. 2001 . Implication of APP secretases in notch signaling . J Mol Neuroscience 17 : 171-181 .
19. Micchelli, C.A., Esler, W.P., Kimberly, W.T. et al. 2003 . Gamma-secretase/presenilin inhibitors for Alzheimer ' s disease phenocopy notch mutations in Drosophila . FASEB J 17 : 79-81 .
20. Siemers, M.E., Skinner, M., Dean, M.P., Gonzales, M.C., and Satterwhite, P.J. 2008 . Safety, tolerability and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers . Clin Neuropharmacol 28 : 126-132 .
21. Siemer, M.E., Quinn, J., Kaye, M.J., Farlow, M.M., Porsteinsson, M.A., Tariot, M.P. et al. 2006 . The effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer ' s disease . Neurology 66 : 602-604 .
22. Fleisher, A.S., Raman, P.R., Siemers, M.E., Becerra, M.L., Clark, M.C., Dean, M.R. et al. 2008 . Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer ' s disease . Clin Trials 65 : 1031-1038 .
23. Bateman, R.J. 2008 . A β turnover in human subjects . Alzheimers Dement 2 :T123-T124 .
24. Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Tarasheski, K.E., and Holtzman, D.M. 2006 . Human anyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo . Nat Med 12 : 1-6 .
25. Bateman, R.J., Wen, G., Morris, J.C., and Holtzman, D.M. 2007 . Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker . Neurology 68 : 666-669 .
26. Hernandez, S.-M.I., Del Rio, J., Moreno, F., and Avila, J. 2007 . Tramiprosate, a drug of potential interest for the treatment of Alzheimer ' s disease, promotes an abnormal aggregation of tau . Mol Neurodegener 2 : 17 .
27. Wilcock, G., Black, S., Hendrix, S., Zavitz, K., Swabb, E., and Laughlin, M. 2008 . Efficacy and safety of tarenflurbil in mild to mederate Alzheimer ' s disease: a randomised phase II trial . Lancet Neurol 7 : 483-493 .
28. Green, R.C., Schneider, L.S., Hendrix, S.B., Zavitz, K.H., and Swabb, E. 2008 . Safety and efficacy of Tarenflurbil in subjects with mild Alzheimer ' s disease: results from an 18-month multi-center phase 3 trial . Alzheimers Dement 2 :T165 .
29. Eriksen, J., Sagi, S., Smith, T.W., Das, P., McLendon, D., Ozols, V. et al. 2003 . NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abert 42 in vivo . J Clin Invest Aug. 112 ( 3 ): 440-449 .
30. Kukar, T., Prescott, S., Eriksen, J., Holloway, V., Murphy, M., Koo, E. et al. 2007 . Chronic administration of R-flurbioprofen attenuates learning impariments in transgenic amyloid precursor protein mice . BMC Neuroscience 8 : 54 .
31. Galasko, D., Graff-Radford, N., May, S., Hendrix, S., Cottrel, B.S., Sagi, S. et al. 2007 . Safety, tolerability, pharmacokinetics and Abeta levels after short-term administration of R-Flurbiprofen in healthy elderly individuals. Alzheimer ' s Disease Association Disorder Oct.-Dec. 21 ( 4 ): 292-299 .
32. Roher, A.E., Esh, C.L., Kokjohn, T.A., Castano, E., Van Vickle, G.D., Kalback, W.M. et al. 2009 . Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer ' s disease . Alzheimers Dement 5 : 18-29 .
33. Kuo, Y.-M., Kokjohn, T.A., Watson, D.M., Woods, A.S., Cotter, R.J., Sue, L.I. et al. 2000 . Elevated A β 42 in skeletal muscle of Alzheimer disease suggests peripheral alterations of A β PP metabolism . Am J Pathol 156 : 797-805 .
34. Slemmon, R.J., Painter, C.L., Nadanaciva, S., Catana, F., Cook, A., Motter, R. et al. 2007 . Distribution of A β peptide in whole blood . J Chromatogr B 846 : 24-31 .
35. Tang, K., Hynan, L.S., Baskin, F., and Rosenberg, R.N. 2006 . Platelet amyloid precursor protein processing: a bio-marker for Alzheimer ' s disease . J Neurol Sci 240 : 53-58 .
36. Moore, K., Zhu, H., Rajapakse, S., Simon, A.J., Pudvah, N.T., Hochman, J.H. et al. 2007 . Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors . Bioorg Med Chem Lett 17 : 5831-5835 .
37. Kandimalla, K., Curran, G.L., Holasek, S., Gilles, E.J., Wengenack, T., and Podusio, J.F. 2005 . Pharmacokinetic analysis of the blood-brain barrier transport of 125 I-amyloid β protein 40 in wild-type and Alzheimer ' s disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation . J Pharmacol Exp Ther 313 : 1370-1378 .
38. Gierdraitis, V., Sundelof, J., Irizarry, M., Garevik, N., Hyman, B.T., Wahlund, L.-O. et al. 2007 . The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer ' s disease . Neurosci Lett 427 : 127-131 .
39. Cummings, J.L. 2008 . Optimizing phase II of drug development for disease-modifying compounds . Alzheimers Dement 4 : S15-S20 .
40. Braak, H. and Braak, E. 1991 . Neuropathological stageing of Alzheimer-related changes . Acta Neuropathol (Berl) 82 : 239-259 .
41. Seab, J., Jagust, W., and Wong, S. 1988 . Quantitative NMR measurements of hippocampal antrophy in Alzheimer ' s disease . Magn Reson Med 8 : 200-208 .
42. Kido, D., Caine, E., and LeMay, M. 1989 . Temporal lobe antrophy in patients with Alzheimer ' s disease: a CT study . AJNR 10 : 551-555 .
43. de Leon, M., George, A., Stylopoulos, L., Smith, G., and Miller, D. 1989 . Early marker for Alzheimer ' s disease: the atrophic hippocampus . The Lancet 2 : 672-673 .
44. Hua, X., Leow, A., Parikshak, N., Lee, S., Chiang, M., Toga, A. et al. 2008 . Tensor-based morphometry as a neuroimaging biomarker for Alzheimer ' s disease: an MRI study of 676 AD, MCI and normal subjects . Neuroimage 43 : 458-469 .
45. Jack, C., Bernstein, M., Fox, N., Thompson, P., Alexander, G., Harvey, D. et al. 2008 . The Alzheimer ' s disease neuroimaging initiative (ADNI); MRI methods . J Magn Reason Imaging 27 : 685-691 .
46. Jack, C., Petersen, R., and Xu, Y. 1998 . Rate of medial temporal lobe atrophy in typical aging and Alzheimer ' s disease . Neurology 51 : 993-999 .
47. Petersen, R., Jack, C., and Xu, Y. 2000 . Memory and MRI-based hippocampal volumes in aging and AD . Neurology 54 : 581-587 .
48. Fox, N.C., Crum, W.R., Scahill, R.I. et al. 2001 . Imaging of onset and progression of Alzheimer ' s disease with voxel-compression mapping of serial magnetic reasonance images . The Lancet 358 : 201-205 .
49. Misra, C., Fan, Y., Davatzikos, C. 2009 . Baseline and longitudinal patterns of brain antrophy in MCI patients, and their use in prediction of short-term conversion of AD: results from ADNI . Neuroimage 44 : 1415-1422 .
50. Mathis, C., Lopresti, B., and Klunk, W. 2007 . Impact of amyloid imaging on drug development in Alzheimer ' s disease . Nucl Med Biol 34 : 809-822 .
51. Henriksen, G., Yousefi, G., Drzezga, A., and Wester, H. 2008 . Development and evaluation of compounds for imaging of beat-amyloid plaque by means of positron emission tomography . Eur J Nucl Med Mol Imagining 35 : S75-S81 .
52. Sperling, R. 2007 . Functional MRI studies of associative encoding in normal agind, mild cognitive impairment, and Alzheimer ' s disease . Ann N Y Acad Sci 1097 : 146-155 .
53. Vandermeeren, M., Mercken, M., and Vanmechelenk, E. 1993 . Detection of tau proteins in normal and Alzheimer ' s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immuno . J Neurochem 61 : 1828-1834 .
54. Motter, R., Vigo-Pelfrey, C., and Kholodenko, D. 1995 . Reduction of beta-amyloid peptide-42 in the cerebrospinal fluid of patients with Alzheimer ' s disease . Ann Neurol 38 : 643-648 .
55. Arai, H. and Terajima, M.M. 1995 . Tau in cerebrospinal fluid; a potential diagnostic marker in Alzheimer ' s disease . Ann Neurol 38 : 649-652 .
56. Andreasen, N., Vanmechelen, E., and Van de Voorde, A. 1998 . Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer ' s disease; a community ased follow up study . J Neurol Neurosurg Psychiatry 64 : 298-305 .
57. Galasko, D., Chang, L., and Motter, R. 1998 . High cerebrospinal fluid tau and low amyloid beta42 levels in clincial diagnosis of Alzheimer disease and relation to apoliopoprotein E genotype . Arch Neurol 55 : 937-945 .
58. Hulstaert, F., Blennow, K., and Ivanoiu, A. 1999 . Improved discrimination of AD patients using beta-amyloid and tau levels in CSF . Neurology 52 : 1555-1562 .
59. Sunderland, T., Linker, G., and Mirza, M. 2003 . Decreased beta amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer ' s disease . JAMA 289 : 2094-2103 .
60. Dubois, B., Geldman, H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, J. et al. 2007 . Research criteria for the diagnosis of Alzheimer ' s disease; revising the NINCDS-ADRDA criteria . The Lancet 6 : 734-746 .
61. Cummings, J. 2006 . Challenges to demonstrating disease-modifying effects in Alzheimer ' s disease clinical trials . Alzheimers Dement 2 : 263-271 .
62. Parkinson Study Group . 2004 . A controlled, randomized, delayed-start study of rasagiline in early Parkinson ' s disease . Arch Neurol 61 : 561-566 .
63. Mohs, R., Knopman, D., Petersen, R., Ferris, S., Ernesto, C., Grundman, M. et al. 1997 . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer ' s disease assessment scale that broadens its scope: the Alzehimer ' s disease cooperative study . Alzheimer ' s Disease Assoc Disord 11 : S13-S21 .
64. Harrison, J., Psychol, C., Minassian, S., Jenkins, L., Black, R., Koller, M. et al. 2007 . A neuropsychological test battery for use in Alzheimer disease clinical trials . Arch Neurol 64 : 1323-1329 .
65. Leber, P. 1990 . Guidelines for the Clinical Evaluations of Antidementia Drugs . Washington, DC : Food & Drug Administration .
66. Scheider, L. and Olin, J.D. 1997 . Validity and reliability and the Alzheimer ' s disease cooperative study-clinical global impressions of change . Alzheimer ' s Disease Assoc Disord 11 : S22-S32 .
67. Knopman, D.K., Gracon, S., and Davis, C. 1994 . The clinicians interview-based impression (CIBI): a clinicians global change rating scale in Alzheimer ' s disease . Neurology 44 : 2315-2321 .
68. Doody, R.S. 2008 . We should not distinguish between symptomatic and disease-modifying treatment in Alzheimer ' s disesase drug development . Alzheimers Dement 4 : S21-S25 .
69. Morris, J., Ernesto, C., Schafer, K., Coats, M., Leon, S., Sano, M. et al. 1997 . Clinical dementia rating training and reliability and reliability in mullticenter studies: the Alzheimer ' s disease cooperative study experience . Neurology 48 : 1508-1510 .
70. Misra, C., Fan, Y., and Davatzikos, C. 2008 . Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI . Neuroimage 44 : 1415-1422 .